Advancing technology has provided clinicians with ever more powerful and effective drugs for treating diseases. As more drugs become available, it becomes progressively more difficult to be aware of the numerous side effects, contraindications, and drug interactions of the many cardiopulmonary drugs available.
Advancing technology has provided clinicians with ever more powerful and effective drugs for treating diseases. As more drugs become available, it becomes progressively more difficult to be aware of the numerous side effects, contraindications, and drug interactions of the many cardiopulmonary drugs available. This seminar has been designed in the hope of facilitating rational drug selections for the treatment of cardiopulmonary diagnosis. For a more exhaustive review of individual drugs, the reader should refer to the package insrt and references. The reader should also follow the current veterinary literature, as new dosing recommendations may become available as a result of clinical use and scientific research. This advice is especially appropriate for new or infrequently used drugs. A handout of drugs and drug dosages, etc. will possibly be made available at seminar, or you can request a copy (email: tilleyvetmed@earthlink.net).
The following is a classification of some common drugs that are used in treating cardiac disease in the dog and cat:
References
Tilley, L.P.; Smith, F.W.K., Jr. (Eds): The Five Minute Veterinary Consult-Canine & Feline Medicine 4th Edition. Ames, Iowa, Wiley Blackwell Publishing, 2008.
Tilley, L.P.; Smith, F.W.K. Jr.; Oyama, M.; and Sleeper, M.: Manual of Canine & Feline Cardiology, 4th Edition.Elsevier, St. Louis, 2008.
Kittleson, M.D.; Kienle, R.D.: Small Animal Cardiovascular Medicine. Philadelphia, Mosby, 1998.
Norsworthy, G.; Crystal, M.; Fooshee, S.; Tilley, L.P.: The Feline Patient, 4th Edition. Ames, Iowa, Wiley Blackwell Publishing, 2010 (in press).
Oral solution approved by the FDA for canine heart failure
November 22nd 2024Vetmedin Solution from Boehringer Ingelheim is indicated for treatment of cases caused by myxomatous mitral valve disease or dilated cardiomyopathy and is the first oral solution approved by the FDA for this use in dogs
Read More
Podcast CE: Canine cardiology: the practical guide to the mitral valve patient
July 19th 2023Learn about the prevalence of myxomatous mitral valve disease, guidelines for staging heart disease, proactive diagnostic workup, the importance of spironolactone and aldosterone blocking, and the benefits of combination therapy for improved outcomes in canine patients
Listen